A Framework for Fitness-for-Purpose and Reuse in Computational Phenotyping
November 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Macrilen
Synonyms :
macimorelin
Class :
Diagnostics, Endocrine
Brand Name :
Macrilen
Synonyms :
macimorelin
Class :
Diagnostics, Endocrine
Dosage Forms & Strengths Â
Granules for oral solution Â
60mg/packet Â
0.5 mg/kg orally after an 8-hour fast
Recommendations before use:
Prior to administering macimorelin, a sufficient washout time of drugs known to prolong the QT interval is recommended.
Discontinue strong CYP3A4 inducers and GH therapy.
Safety and efficacy not establishedÂ
Refer to adult dosingÂ
may decrease the therapeutic effect when combined with growth hormone analogs
may decrease the therapeutic effect when combined with growth hormone analogs
bazedoxifene/conjugated estrogens
may decrease the therapeutic effect when combined with growth hormone analogs
may decrease the therapeutic effect when combined with growth hormone analogs
may decrease the therapeutic effect when combined with growth hormone analogs
may decrease the diagnostic effect of growth hormone affecting products
estrogens esterified/methyltestosterone            Â
may decrease the therapeutic effect of estrogen derivatives
cyproterone and ethinyl estradiolÂ
may decrease the therapeutic effect of Estrogen Derivatives
etonogestrel/ethinyl estradiolÂ
may diminish the therapeutic effect of estrogen derivatives
may decrease the therapeutic effect when combined with growth hormone analogs
may decrease the therapeutic effect when combined with growth hormone analogs
may diminish the hypoglycemic effect
may diminish the hypoglycemic effect
may diminish the hypoglycemic effect
may diminish the hypoglycemic effect
may diminish the hypoglycemic effect
may diminish the diagnostic effect of macimorelin
may diminish the diagnostic effect of macimorelin
may diminish the diagnostic effect of macimorelin
may diminish the diagnostic effect of macimorelin
may diminish the diagnostic effect of macimorelin
may decrease the serum concentration of macimorelin
may decrease the serum concentration of macimorelin
may decrease the serum concentration of macimorelin
may decrease the serum concentration of macimorelin
may decrease the serum concentration of macimorelin
may decrease the diagnostic effect of macimorelin
may decrease the diagnostic effect of macimorelin
may decrease the diagnostic effect of macimorelin
may decrease the diagnostic effect of macimorelin
may decrease the diagnostic effect when combined with macimorelin
may decrease the diagnostic effect when combined with macimorelin
may decrease the diagnostic effect when combined with macimorelin
may decrease the diagnostic effect when combined with macimorelin
may decrease the diagnostic effect when combined with macimorelin
both lapatinib and macimorelin increase the QTc interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of macimorelin
when used with atropine, macimorelin shows unspecified drug interaction
somatostatin analogs decrease the diagnostic effect of macimorelin
scopolamine and macimorelin interact with each other due to an unspecified reaction mechanism
may increase the QTc interval when combined
may decrease the diagnostic effect of corticosteroids
may decrease the diagnostic effect of macimorelin
may decrease the diagnostic effect when combined with macimorelin
may decrease the diagnostic effect of atropine
may decrease the diagnostic effect of nonsteroidal anti-inflammatory agents
may decrease the therapeutic effect of Anticholinergic Agents
Corticosteroids may diminish the therapeutic effect of Growth Hormone Analogs
Corticosteroids may diminish the therapeutic effect of Growth Hormone Analogs
Corticosteroids may diminish the therapeutic effect of Growth Hormone Analogs
Corticosteroids may diminish the therapeutic effect of Growth Hormone Analogs
Corticosteroids may diminish the therapeutic effect of Growth Hormone Analogs
may diminish the diagnostic effect of macimorelin
may diminish the diagnostic effect of macimorelin
may diminish the diagnostic effect of macimorelin
may diminish the diagnostic effect of macimorelin
may diminish the diagnostic effect of macimorelin
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
macimorelin: it may enhance the toxic effect of Anti-Inflammatory Agents
macimorelin: it may enhance the toxic effect of Anti-Inflammatory Agents
aspirin, chlorpheniramine, and phenylephrine
macimorelin: it may enhance the toxic effect of Anti-Inflammatory Agents
macimorelin: it may enhance the toxic effect of Anti-Inflammatory Agents
macimorelin: it may enhance the toxic effect of Anti-Inflammatory Agents
fedratinib increases the effect of macimorelin by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
may diminish the therapeutic effect
may decrease the therapeutic effect of corticosteroids
may decrease the serum concentration of CYP3A4 Inducers
may diminish the therapeutic effect
may diminish the therapeutic effect
bazedoxifene/conjugated estrogens
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
Frequency Defined Â
>10% Â
Bronchitis (12%) Â
Nasopharyngitis (20%) Â
Anemia (13%) Â
Headache (14%) Â
1-10% Â
Hemoglobin <10 g/dL (8.7%) Â
Urinary tract infection (9%) Â
Influenza (6%) Â
Elevated aminotransferases >8 x ULN (2.1%) Â
Elevated aminotransferases >3 x ULN (3.4%)
Pregnancy warnings:    Â
Pregnancy: N/AÂ
Lactation:  Â
Excreted into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.   Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name:Â Â
macimorelin Â
Why do we use macimorelin?Â
macimorelin is a Diagnostics, Endocrine. It is used to diagnose growth hormone deficiency (GHD) in adults. It works by stimulating the production and release of growth hormone from the pituitary gland. Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
